Tudriqev Becomes Only the Second Approved Option for Immunotherapy-Resistant Melanoma

Introduction

Replimune's Tudriqev (vusolimogene oderparepvec-wtpg) has become only the second FDA-approved treatment for patients with advanced melanoma whose disease has progressed after anti-PD-1-based immunotherapy.

The U.S. Food and Drug Administration granted accelerated approval to Tudriqev on August 6, 2026, for use in combination with nivolumab in adults with unresectable advanced cutaneous melanoma following progression on a PD-1-blocking antibody regimen. The approval is particularly significant because treatment options for this patient population have remained extremely limited.

A Very Limited Treatment Landscape

Patients whose advanced melanoma progresses after anti-PD-1 therapy represent a particularly difficult-to-treat population.

FDA briefing materials prepared for the Tudriqev advisory committee noted that treatment options after progression on anti-PD-1-based therapy are limited and generally associated with poor outcomes. Before Tudriqev's approval, lifileucel (Amtagvi) was the only FDA-approved therapy specifically available for patients with melanoma previously treated with anti-PD-1 therapy.

Tudriqev therefore does more than add another drug to the melanoma market. It expands the number of FDA-approved therapeutic approaches available after immunotherapy resistance.

How Tudriqev Compares With the Existing Option

The first approved option in this setting, lifileucel, is a tumor-infiltrating lymphocyte (TIL) therapy. It involves collecting immune cells from a patient's tumor, expanding them outside the body, and then administering them back to the patient as part of an intensive treatment process.

Tudriqev takes a fundamentally different approach.

It is a genetically modified oncolytic viral therapy based on a modified herpes simplex virus. The treatment is injected directly into tumors, where it is designed to destroy tumor cells and stimulate an immune response that can potentially attack cancer cells elsewhere in the body.

This difference could give physicians another therapeutic strategy when treating patients whose melanoma has stopped responding to checkpoint inhibitor therapy.

Tudriqev Uses a Different Immunotherapy Strategy

Tudriqev is designed to combine direct tumor destruction with immune-system activation.

The genetically modified virus is administered directly into accessible tumors. Once inside the tumor environment, it is designed to replicate selectively in cancer cells, contributing to tumor-cell destruction while also promoting an immune response.

Tudriqev is approved in combination with nivolumab, an established PD-1-blocking immunotherapy. The combination is intended to stimulate and enhance an anti-tumor immune response.

This mechanism distinguishes Tudriqev from conventional systemic immunotherapies and from cell-based treatments such as lifileucel.

Clinical Evidence Behind the Approval

The FDA's accelerated approval was based on data from an open-label, multiregional, single-arm clinical trial involving 140 adults with advanced melanoma whose disease had progressed following prior anti-PD-1-based therapy.

Of the patients enrolled, 91 were evaluable for efficacy. The objective response rate was approximately 24%, meaning roughly one in four evaluable patients experienced a measurable tumor response. The median duration of response was 14.1 months.

These results were considered meaningful in a patient population where therapeutic options are particularly limited.

However, because the approval was granted through the accelerated approval pathway, Replimune must conduct additional studies to verify and further characterize the treatment's clinical benefit. Continued approval may depend on the results of these confirmatory trials.

Why the Approval Was Significant

Tudriqev's approval came after an unusually challenging regulatory process.

Replimune had previously faced two FDA rejections before submitting the therapy for a third review. Questions surrounding the single-arm design of the IGNYTE study and the contribution of Tudriqev to the combination with nivolumab were central to the regulatory debate.

The FDA advisory committee subsequently voted 10–3 that the efficacy results were evaluable and clinically meaningful. The favorable vote became an important turning point before the agency ultimately granted accelerated approval.

A New Option for Patients With Few Alternatives

The importance of Tudriqev's approval is closely connected to the unmet medical need in immunotherapy-resistant melanoma.

Many patients with advanced melanoma initially benefit from immune checkpoint inhibitors, but some eventually experience disease progression. Once the disease progresses after anti-PD-1-based therapy, treatment becomes substantially more difficult.

FDA briefing materials highlighted that subsequent therapies can have low response rates, limited durability, significant toxicity, or complicated treatment requirements.

The availability of a second FDA-approved treatment gives oncologists another option when deciding how to manage these patients.

Potential Competitive Advantage

Tudriqev could also have an important competitive distinction because of its administration method.

While lifileucel is a highly complex cell therapy requiring tumor tissue collection and subsequent manufacturing, Tudriqev is administered directly into tumors by a healthcare professional.

This does not mean Tudriqev is suitable for every patient. Tumor accessibility and the patient's clinical circumstances will influence whether direct injection is feasible. Nevertheless, the different treatment approach could help Replimune establish a distinct position in the market.

Reuters reported that analysts see commercial potential for Tudriqev partly because of its safety profile and its less invasive administration compared with lifileucel.

Commercial Importance for Replimune

The approval is also transformative for Replimune because Tudriqev is the company's first approved product.

Replimune now moves from primarily developing experimental therapies to operating as a commercial biotechnology company. The company must build physician awareness, establish treatment centers, secure reimbursement, manage distribution, and ensure that eligible patients can access the therapy.

The commercial opportunity is significant because Tudriqev is entering a market where physicians have relatively few approved choices for patients who have failed anti-PD-1 therapy.

A High-Value but Expensive Treatment

The commercial opportunity also comes with a substantial price.

Replimune has set Tudriqev's U.S. list price at approximately $450,000 per treatment course. The list price does not necessarily represent the final amount paid by insurers or patients because negotiated discounts, reimbursement arrangements, and assistance programs can affect actual costs.

The high price means that demonstrating durable clinical benefit will be particularly important as insurers and healthcare providers evaluate the therapy's value.

Accelerated Approval Keeps the Evidence Question Open

Although Tudriqev is now FDA-approved, its accelerated approval means that additional clinical evidence remains essential.

The FDA requires Replimune to conduct post-approval studies to verify and describe the treatment's clinical benefit. If confirmatory research does not establish the expected benefit, the therapy's long-term regulatory status could be affected.

This creates an important next stage for Replimune: the company must now move beyond demonstrating promising response rates and establish the treatment's benefit through additional evidence.

What Tudriqev Means for Melanoma Treatment

Tudriqev's approval represents a broader shift in melanoma treatment toward increasingly diverse immunotherapy strategies.

Instead of relying exclusively on checkpoint inhibitors, researchers are exploring approaches that combine immune activation, engineered viruses, cellular therapies, targeted treatments, and other mechanisms.

Tudriqev's approval demonstrates the potential of oncolytic immunotherapy to address treatment-resistant disease and gives physicians another tool for a population with significant unmet medical needs.

Conclusion

Tudriqev's FDA approval marks a major development in the treatment of immunotherapy-resistant advanced melanoma. As only the second FDA-approved treatment specifically available in this post-anti-PD-1 setting, it expands a treatment landscape that has historically offered patients very few options.

Its genetically engineered viral approach also gives physicians a treatment strategy that differs substantially from existing cell-based therapy. The combination of direct tumor injection and immune activation could make Tudriqev an important addition to the melanoma treatment landscape.

For Replimune, however, approval is only the beginning. The company must now demonstrate the treatment's long-term clinical value through confirmatory studies while overcoming the challenges of reimbursement, pricing, and commercial adoption.

If Tudriqev's clinical benefit is confirmed, its approval could represent an important step toward expanding treatment options for melanoma patients whose disease has stopped responding to conventional immunotherapy.